Colombia Diabetes Care Devices Market Overview, 2031

Key Insights

• According to the research report, " Colombia Diabetes Care Devices Market Outlook, 2031," published by Bonafide Research, the Colombia Diabetes Care Devices Market is anticipated to grow at more than 11.78% CAGR from 2026 to 2031.
• The Colombian diabetes care devices market operates within a multi-tiered public health system (Sistema General de Seguridad Social en Salud - SGSSS) managed by Health Promoting Entities (Empresas Promotoras de Salud - EPS). Under the statutory Health Benefits Plan (Plan de Beneficios en Salud - PBS, formerly POS), basic blood glucose monitoring (BGM) meters, test strips, lancets, and human insulin injection pens are fully covered for insured patients without substantial out-of-pocket expenses. A major operational and policy breakthrough in Colombia centers on continuous glucose monitoring (CGM) and automated insulin pump access.
• Regulatory approvals and sanitary clearances for diabetes hardware in Colombia are governed nationally by INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos). Recent administrative streamlining by INVIMA has accelerated registration pathways for connected health devices, factory-calibrated 14-day continuous biosensors, and smart insulin pen accessories. A key technological breakthrough includes the integration of continuous glucose sensor output with mobile health applications and regional telemedicine portals.
• Crucially, an estimated 1.2 million adults remain formally undiagnosed, while over 3.5 million present with Impaired Fasting Glucose (IFG) or prediabetes. Type 1 diabetes affects tens of thousands of individuals across the country, including over 12,000 children and adolescents. From an economic perspective, direct healthcare expenditure allocated to managing diabetes and its severe vascular complications in Colombia exceeds $2.8 billion USD annually. The high burden of Type 2 diabetes is driving public health authorities to prioritize continuous self-management tools to prevent acute hospital readmissions and chronic renal complications.

Market Outlook

• The future landscape of Colombia's diabetes care device sector centers on expanding direct-to-consumer (DTC) digital distribution, retail pharmacy e-commerce networks, and accessible biosensing models. Major retail pharmacy chains (such as Farmacias Cruz Verde, Droguerías La Rebaja, Farmatodo, and Droguerías Olímpica) serve as primary access points where private out-of-pocket patients purchase over-the-counter continuous sensors, glucometer consumables, and insulin pen needles. As consumer familiarity with real-time metabolic tracking grows, manufacturers are introducing prescription-light, non-invasive continuous biosensors and smart pen caps that connect directly to consumer smartphones, facilitating proactive glycemic management outside institutional hospital channels.
• Medical device registrations, sanitary clearances, and post-market safety are governed nationally by INVIMA, while public health technology policies are established by the Ministry of Health and Social Protection (MinSalud). Scientific research, clinical guidelines, and patient support frameworks are championed by prominent organizations including the Asociación Colombiana de Diabetes (ACD), the Federación Diabetológica Colombiana, the Asociación Colombiana de Endocrinología, Diabetes y Metabolismo (ACE), and Voces Diabetes Colombia. Prominent commercial companies leading the market in Colombia include Abbott Laboratories Colombia, Dexcom, Medtronic Colombia, Roche Diabetes Care Colombia, Ascensia Diabetes Care, BD (Becton, Dickinson and Company), and Ypsomed.

Market Dynamics

Driver: Mandatory health benefits plan (PBS) coverage protections
The primary growth driver for the Colombian diabetes care devices market is the country's comprehensive statutory health framework (Sistema General de Seguridad Social en Salud - SGSSS) and its statutory Health Benefits Plan (Plan de Beneficios en Salud - PBS). Under national healthcare regulations, Health Promoting Entities (Empresas Promotoras de Salud - EPS) are legally required to provide full coverage for foundational diabetes diagnostic equipment, self-monitoring blood glucose (SMBG) meters, test strips, lancets, and human insulin pen delivery systems at little to no out-of-pocket cost for insured patients.
Challenge: EPS liquidity bottlenecks, administrative delays, and regional health inequities
Despite strong legal protections, market expansion in Colombia is heavily constrained by financial liquidity pressures within the EPS network, administrative authorization delays, and stark geographic inequities. Many EPS entities face severe cash-flow deficits, leading to prolonged payment cycles to medical device distributors and delayed fulfillment of high-tech device prescriptions. Navigating the MIPRES authorization or legal Tutela process to obtain continuous glucose monitors or sensor-augmented insulin pumps can take months, creating significant administrative friction for patients and healthcare providers.
Trend: Penetration of retail e-pharmacies, direct-to-consumer biosensing, and tele-health integrations
A major trend reshaping Colombia’s diabetes care market is the rapid migration toward retail pharmacy e-commerce channels paired with mobile-first digital health platforms. Major retail pharmacy chains such as Farmacias Cruz Verde, Droguerías La Rebaja, Farmatodo, and Droguerías Olímpica have expanded their digital storefronts to become primary direct-to-consumer (DTC) channels for non-prescription continuous biosensors, glucometer consumables, and smart pen accessories. Parallel to this commercial shift, device manufacturers are pairing continuous glucose sensors with mobile applications and cloud-connected telemetry software.

Segment Analysis

Colombia Diabetes Care Devices By Product Type
• Colombia’s blood glucose monitoring systems market combines conventional glucometers and test strips with continuous and flash glucose monitoring technologies. Traditional systems remain practical for patients who need affordable, straightforward testing, while sensor-based devices offer a more detailed view of glucose patterns between clinical appointments. Colombia’s varied geography makes dependable distribution and access to replacement consumables particularly important for patients outside major urban centers. Another distinctive consideration is that monitoring platforms from different manufacturers may use separate applications and data portals, creating opportunities for interoperable software and simpler reporting.
• Colombia’s insulin delivery devices market includes syringes, insulin pens, and insulin pumps, with product selection influenced by clinical needs, coverage arrangements, affordability, and access to specialist support. Pens offer convenient administration for many patients, whereas pumps provide more flexible insulin delivery for selected individuals requiring intensive management. A distinctive feature of the market is the importance of demonstrating clinical need and navigating insurer authorization processes when accessing advanced technologies.



Colombia Diabetes Care Devices By Disease Type
• Colombia’s type 1 diabetes segment requires consistent insulin delivery, frequent glucose monitoring, and access to specialized clinical guidance. Insulin pumps and sensor-based monitoring technologies are particularly relevant for patients who need intensive treatment, while conventional meters remain important for backup testing and situations in which sensor readings require confirmation. Access to advanced systems can depend on insurance coverage, clinical eligibility, and specialist oversight. Manufacturers can differentiate themselves through integrated monitoring and insulin-delivery solutions, pediatric-friendly devices, dependable replacement supplies, and Spanish-language training for patients and caregivers.
• Colombia’s type 2 diabetes segment requires monitoring options suited to a broad range of treatment pathways, from lifestyle management and oral medication to insulin therapy. Conventional glucose meters remain practical for routine self-monitoring, while continuous glucose monitoring can provide additional insights for selected patients who need closer evaluation of glucose responses to food, physical activity, and medication. Affordability, insurer coverage, and access to clinical follow-up influence which technologies are practical for individual patients.

Colombia Diabetes Care Devices By End User
• Colombia’s home and self-care segment is shaped by the need to manage diabetes between medical appointments while navigating differences in healthcare access across urban, rural, and geographically remote communities. Glucose meters, test strips, insulin pens, and continuous glucose monitors support different monitoring and treatment requirements. Consistent access to consumables and clear guidance on device use are essential to maintaining long-term engagement. Connected applications can help patients share readings with healthcare professionals, but fragmented manufacturer platforms may complicate the process.
• Hospitals in Colombia use diabetes care devices for inpatient glucose monitoring, insulin administration, treatment adjustment, and patient education. Device selection is influenced by clinical reliability, procurement arrangements, staff training, and the availability of compatible consumables. Hospitals and specialist clinics also play a central role in identifying patients who may benefit from advanced monitoring or insulin pump therapy and helping them navigate the transition to home-based care.
• Colombia’s diagnostic centers contribute to diabetes screening and follow-up by providing laboratory testing and assessments of glycemic control. Their priorities include consistent testing procedures, dependable equipment, quality assurance, and efficient patient processing. Laboratory results complement personal glucose monitoring by helping clinicians evaluate longer-term glycemic control alongside readings collected during everyday activities. Diagnostic centers can strengthen their role by coordinating reports with primary-care physicians, endocrinologists, and other providers involved in ongoing diabetes management.
• Colombia’s ambulatory surgical centers require diabetes care devices that support appropriate glucose assessment and treatment coordination around outpatient procedures. Their priorities include reliable readings, rapid access to results, hygienic device handling, and clear documentation for perioperative teams. Patients may arrive using personal glucose meters, continuous glucose monitors, insulin pens, or insulin pumps, requiring staff to understand existing treatment arrangements and follow appropriate device-management protocols.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Diabetes Care Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Blood Glucose Monitoring Systems
• Insulin Delivery Devices

By Disease Type
• Type 1 Diabetes
• Type 2 Diabetes

By End User
• Home/Self-Care
• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers